Telix Pharmaceuticals Sees 56% Revenue Surge to $804M, Guides $950–$970M in 2026
Telix Pharmaceuticals posted $804 million in 2025 revenue, a 56% increase year-over-year, and $216 million EBITDA, up 25%, with gross margin steady at 53% and cash balance of $142 million. The company launched FDA-approved Gozelix and projects 2026 revenue of $950–$970 million alongside $200–$240 million R&D investment.
1. Financial Results
Telix achieved $804 million in 2025 revenue, up 56% year-over-year, driven by a 22% rise in precision medicine sales to $622 million. EBITDA rose 25% to $216 million, gross margin held at 53%, and year-end cash balance reached $142 million.
2. Product Launch and Pipeline
The company launched FDA-approved Gozelix in 2025, expected to boost future top-line growth. Telix maintains over 30 sponsored and collaborative studies, including pivotal trials poised to deliver key commercial milestones.
3. 2026 Guidance and Investments
Management targets $950–$970 million in 2026 revenue, implying up to 25% precision medicine growth, and plans R&D spending of $200–$240 million to advance its late-stage pipeline.
4. Market Challenges
European reimbursement delays threaten launch timelines, with up to 12-month approval hurdles. Lower gross margins in the RLS segment and intensifying competition introduce risks to growth and profitability, while FDA review timelines remain uncertain.